Dapagliflozin
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated to improve glycemic control in adults with type 2 diabetes. By inhibiting SGLT2 expressed in the kidney, dapagliflozin reduces reabsorption of filtered glucose and thereby promotes urinary glucose excretion.
Dapagliflozin was approved in the EU in 2012, in the US and in Switzerland in 2014.
Therapeutic group
Drugs used in diabetes, sodium-glucose co-transporter 2 (SGLT2) inhibitors
ATC Codes: A10BK01; A10BD15, A10BD21, A10BD25 (combinations)
Dapagliflozin was approved in the EU in 2012, in the US and in Switzerland in 2014.
Therapeutic group
Drugs used in diabetes, sodium-glucose co-transporter 2 (SGLT2) inhibitors
ATC Codes: A10BK01; A10BD15, A10BD21, A10BD25 (combinations)
Dapagliflozin
Key dosage forms
- Film-coated tablets (5mg,10 mg)
Features
- Novel crystal form: Form E, more stable and easy to handle as it doesn't need cold shipment/storage.
- Low patent infringement risk compared with amorphous form, as spontaneous shift to patent forms is avoided.
- Higher melting point (70ºC). Avoids melting problems during manufacture.
- Competitive price
Some brand names
- FORXIGA®, FARXIGA®(ASTRAZENECA)